Co-Host: William Huang, MD

At the conclusion of these activities, participants will be able to:

1. Discuss the current immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Identify and manage the adverse events related to these agents.

CME Available: auau.auanet.org/node/26095

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma